In 2020, dupilumab was covered by health insurance for CRSwNP in Japan and has shown good therapeutic outcomes in the treatment of ECRS, a typical disease of CRSwNP.5, 6 Biologics targeting IL-5 have also been shown to be effective against ECRS,23 and if they become available for administration in Japan, the treatment options for ECRS will increase. This evidence concerns the gene IL5 and chronic rhinosinusitis with nasal polyps.